TRACON Pharmaceuticals Inc is a United States-based biopharmaceutical company which licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The Company�s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company focuses to become the oncology and ophthalmology therapeutics Company. Both TRC105 and TRC102 are being developed for treatment in combination with available therapies.